Company Information

  

Address: 8000 MARINA BOULEVARD
SUITE 300 
City: BRISBANE 
State: CA 
Zip Code: 94005-1884 
Telephone: (650) 614-5220 

Description of Business

Primary SIC Code: 2834
(As filed with the SEC)  

We are a clinical-stage biopharmaceutical company advancing a new therapeutic approach, including the development of proprietary product candidates, for the treatment of peanut and other food allergies. It is estimated that over 30 million people in the United States and Europe have a food allergy, with peanut allergy being the most prevalent and most commonly associated with severe outcomes and life-threatening events. There are currently no approved medical therapies to cure food allergies or prevent their symptoms. Patients with food allergies are typically counseled to practice strict dietary avoidance. When accidental exposure to food allergens invokes a serious allergic reaction, rescue therapies, such as antihistamines or injectable epinephrine, are the only recourse available.  ... More ...  

Per Share Overview

Date 12-mos Rolling EPS Dividend P/E Ratio
06/2018-3.28NAN/E
03/2018-3.01NAN/E
12/2017-2.61NAN/E
09/2017-2.35NAN/E
06/2017-2.24NAN/E
03/2017-2.04NAN/E
12/2016-1.89NAN/E
09/20162.28NA6.58

Key Financial Ratios and Statistics

FYE: 12/31

Profitability 2017 Leverage 2017
Net Inc/Comm Equity-0.30Total Liab/Total Assets0.14
Net Inc/Total Assets-0.63Total Liab/Inv Cap0.16
Net Inc/Inv Cap-0.73Total Liab/Comm Equity0.07
Pretax Inc/Net SalesNAInterest Coverage RatioNA
Net Inc/Net SalesNACurr Debt/EquityNA
Cash Flow/Net SalesNALTD/EquityNA
SG&A/NetSalesNATotal Debt/EquityNA
Asset Utilization   Liquidity  
Net Receivables TurnoverNAQuick Ratio7.11
Inventory TurnoverNACurrent Ratio7.11
Inventory Day SalesNANet Rec/Curr AssetsNA
Net Sales/Work CapNAInv/Curr AssetsNA
Net Sales/PP&ENA  

Income Statement (Millions)

  6/30/2018 3/31/2018 12/31/2017 9/30/2017
Total Revenues(Net Sales) NA NA NA NA
Cost of Goods Sold NA NA NA NA
Selling & Admin Exps 18.56 16.67 12.99 11.23
Operating Income -53.81 -50.12 -41.64 -32.29
Interest Exp NA NA NA NA
Pretax Income -52.52 -49.48 -41.11 -31.79
Other Income 1.29 0.64 0.53 0.50
Net Income Bef Extraordinary ... NA NA NA NA
Net Income -52.55 -49.50 -41.17 -31.79

Balance Sheet (Millions)

Assets 6/30/2018 3/31/2018 12/31/2017 9/30/2017
Cash & Short Term Investments 290.00 321.88 182.43 212.03
Receivables - Total NA NA NA NA
Inventories - Total NA NA NA NA
Total Current Assets 296.83 330.30 189.11 218.09
Net Property, Plant & Equipment 23.27 21.02 17.21 14.94
Total Assets 326.66 361.85 206.93 233.67
Liabilities        
Accounts Payable 36.06 30.38 26.57 21.15
Debt in Current Liabilities NA NA NA NA
Total Current Liabilities 36.09 30.41 26.60 21.19
Long-Term Debt NA NA NA NA
Total Liabilities 38.82 32.75 29.13 23.08
Stockholder's Equity        
Minority Interest NA NA NA NA
Preferred Stock NA NA 0.00 NA
Common Stock 0.01 0.01 0.01 0.01
Retained Earnings -367.54 -314.98 -265.48 -224.32
Treasury Stock NA NA NA NA
Total Stockholders' Equity 287.84 329.09 177.81 210.59
Total Liabilities and Stockholders' Equity 326.66 361.85 206.93 233.67

Cash Flow Summary (Millions)

Categories 6/30/2018 3/31/2018 12/31/2017 9/30/2017
Net Cash Provided by Operating Activities -36.55 -39.76 -31.93 -24.33
Net Cash Provided by Investing Activities -34.98 -15.86 28.03 12.25
Net Cash Provided by Financing Activities 4.36 191.46 3.57 1.45

Annual Summary Data (Millions)

Year Sales Net Income EPS
12/20130.00-4.82--
12/20140.00-11.12--
12/20150.00-35.821.88
12/20160.00-80.82-1.89
12/20170.00-131.32-2.61
Growth RatesNaN----

Stock Ownership

Type Date(Q,M) No. Owners Shares Held (000s) % Own
Institutional06/30/1817745,73078.20




Report Date : 9/24/2018

Powered By Edgar Online © 2018EDGAR®Online, a division of Donnelley Financial Solutions. EDGAR® is a federally registered trademark of the U.S. Securities and Exchange Commission. EDGAR Online is not affiliated with or approved by the U.S. Securities and Exchange Commission.